search

Active clinical trials for "Alopecia"

Results 321-330 of 449

Treatment of Male Pattern Baldness With Botulinum Toxin

Male Pattern Baldness

This proof of concept study seeks to demonstrate that Botulinum toxin injections are a safe and effective method for treating this form of hair loss.

Completed3 enrollment criteria

Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia

Androgenetic Alopecia

The objective of this clinical study is to assess the safety and efficacy of using a laser and hair growth factors in the treatment of male-pattern hair loss. Participating subjects will receive up to two (2) treatments per month for 6 months with the laser and post-treatment topically applied hair growth factors and will have a 6 month follow-up period.

Withdrawn19 enrollment criteria

Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients...

Alopecia Areata

The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.

Completed17 enrollment criteria

A Study of JNJ-64304500 in Participants With Alopecia Areata

Alopecia Areata

The purpose of this study is to evaluate the clinical response of 22 weeks of study intervention with JNJ-64304500, compared with placebo, in participants with moderate to severe alopecia areata (AA).

Withdrawn11 enrollment criteria

Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male...

Androgenetic Alopecia

The objective of this clinical study is to compare the safety and efficacy of a laser and topically applied platelet-rich plasma vs. platelet rich plasma injection in the treatment of male-pattern hair loss. Participating subjects will receive up to four (4) monthly treatments and will have a 12 month follow-up period.

Withdrawn18 enrollment criteria

The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal...

Female Androgenetic Alopecia

The investigators propose to conduct a head-to-head, randomized clinical trial to compare the effectiveness of Minoxidil with Spironolactone and Finasteride in treating postmenopausal females with Androgenetic Alopecia (AGA).

Withdrawn12 enrollment criteria

Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis

Alopecia Totalis/Universalis

Will Abatacept reduce priming of the hair follicle specific T cells and thereby reduce hair follicle associated infiltration and improve hair growth. This is a double blind placebo controlled study to test the safety and efficacy of Abatacept in the treatment of 64 subjects diagnosed with alopecia totalis or alopecia universalis. Subjects will be randomized 1:1 to the placebo or treatment arm and will receive 6 months of treatment with the study medication or placebo, followed by a 6 month observational period.

Withdrawn26 enrollment criteria

A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata

Alopecia Areata

The purpose of this study is to determine if receiving sub-cutaneous injections of a medication called abatacept causes regrowth of hair in people with alopecia areata. Among patients with alopecia areata, patients with worse disease are unlikely to have satisfactory outcomes with current therapies. Our hypothesis is that Abatacept will be effective therapy in moderate to severe alopecia areata by blocking re-activation of a special type of immunecell call a memory T-Cell (CD8+NKG2D+)thereby blocking the inflammatory response underlying alopecia areata.

Withdrawn50 enrollment criteria

Efalizumab in the Treatment of Alopecia, Phase II

Alopecia Totalis

Determine the effect that treatment with efalizumab has on scalp hair re-growth in younger adults affected by severe variants of alopecia areata, including alopecia totalis, alopecia universalis, and severe ophiasis variants.

Withdrawn22 enrollment criteria

Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata

Alopecia AreataAlopecia Totalis1 more

This study is a randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to characterize the efficacy and safety of BNZ-1 administered by slow IV push weekly for 3 months to adults diagnosed with moderate to severe alopecia areata, defined as having a >50% loss of terminal hair on the scalp. The study has three periods: 30-Day Screening Period 3-Month Treatment Period 3-Month Follow-up Period The study will be conducted at approximately 15-20 clinical sites in the United States.

Withdrawn11 enrollment criteria
1...323334...45

Need Help? Contact our team!


We'll reach out to this number within 24 hrs